MAIN STORY
A commercial warning moves beyond speculation
The striking aspect of the presentation obtained by Reuters is not merely its prediction of pressure on sales. Heineken, the world’s second-largest brewer, set out operational suggestions for British hospitality customers, suggesting that a medical trend has become a business-planning question.
Users of GLP-1 medicines may feel full sooner and order fewer drinks during a visit. That threatens occasions historically measured by rounds of pints. Half-pints, low- and zero-alcohol beverages and small food plates are among the options highlighted as venues rethink how customers spend an evening.
Heineken described the material as part of its regular engagement with UK operators. It said some people taking GLP-1 medicines were choosing smaller portions and more premium products rather than abandoning alcohol altogether. The challenge, therefore, is not simply shrinking demand but a changing composition of demand.
What the spending figures reveal
According to Circana research cited by Reuters, US households containing a GLP-1 user spent about 7% less per month on alcohol after two years than households without a user. Their beer spending was around 13.5% lower.

















